Combining with endocrine therapy, PI3K inhibitors alpelisib, AKT inhibitors capivasertib, and mTOR inhibitors everolimus have been applied clinically in breast cancer treatment, especially in hormone receptor (+)/HER2(−) subtypes, to overcome resistance [38, 64]. Here, ERBB2 is linked to breast carcinoma.